Cullinan Therapeutics Inc. announced a corporate update, highlighting key anticipated milestones and preliminary financial results. The company reported unaudited preliminary cash, cash equivalents, short- and long-term investments, and interest receivable totaling $439.0 million as of December 31, 2025. Cullinan expects its cash resources to provide runway into 2029 under its current operating plan. In its clinical portfolio, Cullinan plans data readouts in 2026 for CLN-978 across three autoimmune indications—rheumatoid arthritis, systemic lupus erythematosus, and Sjögren's disease—including both single dose and repeat dosing data. The company will complete monotherapy expansion cohorts for CLN-049 to determine the recommended Phase 2 dose for a pivotal registrational study and aims to initiate a combination study in frontline acute myeloid leukemia (AML) in the fourth quarter of 2026. Additionally, Cullinan expects the rolling NDA submission for zipalertinib to be completed in the first quarter of 2026, with full enrollment of the REZILIENT3 frontline study anticipated in the first half of 2026. Cullinan will report its fourth quarter and full-year 2025 financial results in late February 2026, providing further details on its financial position and results of operations.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cullinan Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9621870-en) on January 08, 2026, and is solely responsible for the information contained therein.